Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1362836

N.N.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TSHR P16473 2/20 0.40
THRB P10828 1/20 0.40
TP53 P04637 1/20 0.40
CA2 P00918 2/20 0.39
CES1 P23141 2/20 0.36
ACLY P53396 2/20 0.35
CA1 P00915 1/20 0.33
CA9 Q16790 1/20 0.33
POLB P06746 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TET2 Q6N021 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3813522 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1TSHRTHRBTP53
Trifluoroacetic Acid SCHEMBL30705423 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1TSHRTHRBTP53
Trifluoroacetic Acid SCHEMBL27922651 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1TSHRTHRBTP53
Trifluoroacetic Acid SCHEMBL4531143 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1TSHRTHRBTP53
Trifluoroacetic Acid SCHEMBL2015479 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1TSHRTHRBTP53
Trifluoroacetic Acid SCHEMBL1025679 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1TSHRTHRBTP53
Trifluoroacetic Acid SCHEMBL4772775 1.00
Trifluoroacetic Acid SCHEMBL375389 1.00
Trifluoroacetic Acid SCHEMBL2484766 0.95 ALDH1A1 (0.44) ALDH1A1L3MBTL1TSHRTHRBTP53
Trifluoroacetic Acid SCHEMBL4598430 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118510762-A As AMPK activators thiadiazolone derivatives 贝塔吉能公司 2024-08-16 CN claimed
US-20250152619-A1 POLYIMIDAZOLIUM-BASED CATIONIC ANTIMICROBIAL POLYMERS FOR NOVEL MASTITIS PROPHYLACTIC SOLUTIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2025-05-15 US disclosed
CN-118804756-A Polyimidazolium-based cationic antimicrobial polymers for novel mastitis prevention solutions 麻省理工学院 2024-10-18 CN disclosed
US-12098147-B2 Compound having novel structure, complex comprising same, anti-cancer pharmaceutical composition, and anti-cancer drug ETNOVA THERAPEUTICS CORP. (KR) 2024-09-24 US disclosed
CN-118510762-A As AMPK activators thiadiazolone derivatives 贝塔吉能公司 2024-08-16 CN disclosed
CN-112533907-B Compounds having novel structures, complexes comprising same, and anti-cancer pharmaceutical compositions and anti-cancer agents 艾特诺瓦治疗公司 2024-02-06 CN disclosed
WO-2023132793-A2 POLYIMIDAZOLIUM-BASED CATIONIC ANTIMICROBIAL POLYMERS FOR NOVEL MASTITIS PROPHYLACTIC SOLUTIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-07-13 WO disclosed
US-20230131111-A1 BIODEGRADABLE POLYIMIDAZOLIUMS AND OLIGOIMIDAZOLIUMS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2023-04-27 US disclosed
EP-4157919-A1 BIODEGRADABLE POLYIMIDAZOLIUMS AND OLIGOIMIDAZOLIUMS Nanyang Technological University (SG) 2023-04-05 EP disclosed
CN-115836103-A Biodegradable polyimidazolium and oligoimidazolium salts 南洋理工大学 2023-03-21 CN disclosed
CN-115667223-A Imidazolium reagents for mass spectrometry 豪夫迈·罗氏有限公司 2023-01-31 CN disclosed
US-20220024911-A1 COMPOUND HAVING NOVEL STRUCTURE, COMPLEX COMPRISING SAME, ANTI-CANCER PHARMACEUTICAL COMPOSITION, AND ANTI-CANCER DRUG ETNOVA THERAPEUTICS CORP. (KR) 2022-01-27 US disclosed
US-8426607-B2 Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-04-23 US disclosed
US-20110288139-A1 SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-24 US disclosed
EP-2245016-A1 SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE Boehringer Ingelheim International GmbH (DE) 2010-11-03 EP disclosed
WO-2009092566-A1 SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-30 WO disclosed
US-6919382-B2 Preparation and uses of conjugated solid supports for boronic acids THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2005-07-19 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
US-20030044840-A1 Preparation and uses of conjugated solid supports for boronic acids GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288139-A1 SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE PSEN1, AADAT, PSEN2 ALDH1A1 735/4885L3MBTL1 3265/4885TSHR 4184/4885
US-20230131111-A1 BIODEGRADABLE POLYIMIDAZOLIUMS AND OLIGOIMIDAZOLIUMS PCNA, CD68, TLR3 ALDH1A1 2489/4885L3MBTL1 1257/4885TSHR 3743/4885
US-12098147-B2 Compound having novel structure, complex comprising same, anti-cancer pharmaceutical composition, and anti-cancer drug TP53, TOP1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ALDH1A1 962/4885L3MBTL1 4678/4885TSHR 4867/4885
US-20030044840-A1 Preparation and uses of conjugated solid supports for boronic acids SLC43A1, SBDS, SLC7A5 ALDH1A1 1529/4885L3MBTL1 3686/4885TSHR 1683/4885
US-20220024911-A1 COMPOUND HAVING NOVEL STRUCTURE, COMPLEX COMPRISING SAME, ANTI-CANCER PHARMACEUTICAL COMPOSITION, AND ANTI-CANCER DRUG TOP1, ABCB1, ABCF1 ALDH1A1 694/4885L3MBTL1 4810/4885TSHR 4863/4885
US-20250152619-A1 POLYIMIDAZOLIUM-BASED CATIONIC ANTIMICROBIAL POLYMERS FOR NOVEL MASTITIS PROPHYLACTIC SOLUTIONS PIM1, PIM3, PIM2 ALDH1A1 4647/4885L3MBTL1 652/4885TSHR 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.